GAMMA Investing LLC Buys 78 Shares of argenx SE (NASDAQ:ARGX)

GAMMA Investing LLC grew its stake in shares of argenx SE (NASDAQ:ARGX) by 44.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 252 shares of the company’s stock after acquiring an additional 78 shares during the quarter. GAMMA Investing LLC’s holdings in argenx were worth $155,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ARGX. FMR LLC boosted its stake in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in shares of argenx during the third quarter valued at $88,339,000. Perpetual Ltd purchased a new stake in shares of argenx during the third quarter valued at $76,314,000. Logos Global Management LP bought a new stake in argenx in the 2nd quarter worth about $58,055,000. Finally, Wellington Management Group LLP raised its position in argenx by 13.0% in the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after buying an additional 55,617 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

Shares of argenx stock opened at $649.26 on Thursday. The company has a fifty day moving average of $611.04 and a 200 day moving average of $545.85. The company has a market capitalization of $39.19 billion, a P/E ratio of -737.80 and a beta of 0.59. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $663.48.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter last year, the business posted ($1.25) earnings per share. Analysts forecast that argenx SE will post 2.2 EPS for the current year.

Analysts Set New Price Targets

ARGX has been the topic of a number of recent analyst reports. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Evercore ISI raised their target price on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Piper Sandler boosted their target price on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and increased their price target for the company from $515.00 to $650.00 in a report on Friday, November 1st. Finally, Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average price target of $645.61.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.